Marcello Arca, Giovanni Pigna and Carla Favoccia Pages 684 - 686 ( 3 )
Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Dipartimento di Medicina Interna e Specialita Mediche, Sapienza Universita di Roma Viale del Policlinico, 155- 00161 Rome, Italy.